(Q38260932)

1 September 2017

title

Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders (English)

1 reference

1 September 2017

1 reference

1 reference

6

Thomas Gasser

1 reference

1 September 2017

1

Lutz UC

1 reference

1 September 2017

2

Sirfy A

1 reference

1 September 2017

3

Wiatr G

1 reference

1 September 2017

4

Altpass D

1 reference

1 September 2017

5

Farger G

1 reference

1 September 2017

7

Karle KN

1 reference

1 September 2017

8

Batra A

1 reference

1 September 2017

language of work or name

English

0 references

publication date

18 October 2014

1 reference

European Journal of Clinical Pharmacology

1 September 2017

published in

1 reference

1 September 2017

volume

70

1 reference

1 September 2017

issue

12

1 reference

1 September 2017

page(s)

1471-1476

1 reference

Prevalence and incidence of Parkinson's disease in Europe

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Parkinson’s disease psychosis 2010: A review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Longitudinal outcome of Parkinson's disease patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

The safety of clozapine in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Current use of clozapine in Parkinson disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Pregnancy decreases rat CYP1A2 activity and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1772-0

21 January 2018

1 reference

12 December 2020

Clinical Risk Management in Dutch Community Pharmacies

1 reference

12 December 2020

Antipsychotic efficacy in relation to plasma levels of clozapine (author's transl)

1 reference

12 December 2020

Medication management in the elderly

1 reference

12 December 2020

Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine

1 reference

12 December 2020

Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women

1 reference

12 December 2020

10.1007/S00228-014-1772-0

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1036647137

0 references

1 reference